This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnoldi, J. Articles by Flad, H. D. Search for Related Content PubMed PubMed Citation Articles by Arnoldi, J. Articles by Flad, H. D.

American Journal of Pathology, Vol 137, 749-753, Copyright © 1990 by American Society for Investigative Pathology

REGULAR ARTICLES

Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy

J Arnoldi, J Gerdes and HD Flad
Department of Immunology and Cell Biology, Forschungsinstitut Borstel, Federal Republic of Germany.

The aim of this study was to determine cytokines in human leprosy lesions by means of immunohistologic examination. Cryostat sections of skin biopsies from 57 patients with various forms of leprosy were immunostained according to the APAAP method, using monoclonal antibodies against interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and, in addition, against CD 1 antigen. Granulomas in biopsies of untreated patients with tuberculoid leprosy showed large amounts of cells positive for IL-1 beta, TNF-alpha, IFN-gamma, and CD 1, whereas no positive signals could be detected in untreated patients with lepromatous leprosy. However, in those biopsies obtained from lepromatous leprosy patients undergoing chemotherapy, positive staining for cytokines as well as subepidermal Langerhans cells increased to a detectable amount. Remarkably, in tuberculoid leprosy patients, the number of IL-1 beta--positive cells did not vary under therapy, while the number of TNF-alpha and IFN-gamma reactive cells decreased. These results suggest that immunohistologic determination of cytokines in combination with the assessment of subepidermal Langerhans cells in human leprosy lesions may be used as a parameter for the patient's status of cell-mediated immunity under chemotherapeutic treatment.

This article has been cited by other articles:

				D. M. Scollard, L. B. Adams, T. P. Gillis, J. L. Krahenbuhl, R. W. Truman, and D. L. Williams The Continuing Challenges of Leprosy Clin. Microbiol. Rev., April 1, 2006; 19(2): 338 - 381. [Abstract] [Full Text] [PDF]

				M. N. WEITZMANN and R. PACIFICI Estrogen Regulation of Immune Cell Bone Interactions Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 256 - 274. [Abstract] [Full Text] [PDF]

				A. K. Andersson, M. Chaduvula, S. E. Atkinson, S. Khanolkar-Young, S. Jain, L. Suneetha, S. Suneetha, and D. N. J. Lockwood Effects of Prednisolone Treatment on Cytokine Expression in Patients with Leprosy Type 1 Reactions Infect. Immun., June 1, 2005; 73(6): 3725 - 3733. [Abstract] [Full Text] [PDF]

				M Yamamura, K Uyemura, R. Deans, K Weinberg, T. Rea, B. Bloom, and R. Modlin Defining protective responses to pathogens: cytokine profiles in leprosy lesions Science, October 11, 1991; 254(5029): 277 - 279. [Abstract] [PDF]